Primary Mechanisms of Tigecycline Resistance
Tigecycline, a glycylcycline antibiotic, targets the bacterial ribosome to inhibit protein synthesis. Resistance emerges mainly through efflux pumps that expel the drug from cells, reducing intracellular concentrations. The most common is overexpression of AdeABC in Acinetobacter baumannii, Tet(X) enzymes in Enterobacteriaceae, and Mef(A) or MexXY pumps in Pseudomonas aeruginosa and other Gram-negatives.[1][2]
Ribosomal protection proteins, like Tet(X1-X7) variants, also confer resistance by binding tigecycline and preventing ribosome interaction. These enzymes, originally from soil bacteria, spread via plasmids.[3]
How Resistance Genes Spread in Populations
Plasmid-mediated transfer accelerates resistance dissemination. Tet(X) genes, for instance, reside on conjugative plasmids, enabling horizontal gene transfer between species like E. coli, Klebsiella pneumoniae, and Enterobacter cloacae. Selective pressure from tigecycline use in hospitals and agriculture drives this.[1][4]
Mutations in efflux regulators (e.g., AdeRS in A. baumannii) upregulate pumps without plasmids, arising de novo under antibiotic exposure.[2]
Key Bacterial Species Affected
Resistance is prevalent in multidrug-resistant pathogens:
- Acinetobacter baumannii: 20-50% resistance rates via AdeIJK and AdeFGH pumps.
- Enterobacteriaceae (e.g., K. pneumoniae): Tet(X4) drives high-level resistance.
- Pseudomonas aeruginosa: MexXY-OprM overexpression.
Lower rates in Enterobacterales overall, but rising in ICU settings.[2][5]
| Species | Main Mechanism | Prevalence |
|---------|----------------|------------|
| A. baumannii | Efflux (AdeABC) | High (up to 50%) |
| K. pneumoniae | Tet(X) enzymes | Emerging (10-30%) |
| P. aeruginosa | MexXY pump | Moderate (15-40%) |
Factors Driving Population-Level Resistance
Hospital overuse and suboptimal dosing (tigecycline's low serum levels select for efflux mutants) fuel resistance. Combination therapy failures allow co-selection with other antibiotics. In livestock, veterinary tigecycline analogs promote Tet(X) reservoirs.[3][4]
Clinical Implications and Detection Challenges
Resistant strains show MICs >8 mg/L, complicating treatment of ventilator-associated pneumonia. PCR or whole-genome sequencing detects Tet(X) or efflux genes; phenotypic tests like disk diffusion often underestimate due to inoculum effects.[5]
Phenotypic screening misses low-level resistance, leading to treatment failures in 20-30% of CRAB cases.[2]
Strategies to Combat Resistance
Efflux inhibitors (e.g., phenylboronic acid derivatives) restore susceptibility in lab models. Dual beta-lactam/tigecycline regimens suppress mutants. Surveillance via CLSI breakpoints (MIC ≤2 mg/L susceptible) guides use.[1][5]
Sources
[1] Tigecycline Resistance Mechanisms - Clinical Microbiology Reviews
[2] Efflux Pumps in A. baumannii - Antimicrobial Agents and Chemotherapy
[3] Tet(X) Plasmid Spread - Nature Communications
[4] Veterinary Selective Pressure - Emerging Infectious Diseases
[5] CLSI Guidelines on Tigecycline - CLSI M100